Compare · GPCR vs LITS
GPCR vs LITS
Side-by-side comparison of Structure Therapeutics Inc. (GPCR) and Lite Strategy Inc. (LITS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GPCR and LITS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- GPCR is the larger of the two at $1.43B, about 56.6x LITS ($25.3M).
- LITS has been more active in the news (8 items in the past 4 weeks vs 6 for GPCR).
- GPCR has more recent analyst coverage (16 ratings vs 0 for LITS).
- Company
- Structure Therapeutics Inc.
- Lite Strategy Inc.
- Price
- -
- -
- Market cap
- $1.43B
- $25.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2003
- News (4w)
- 6
- 8
- Recent ratings
- 16
- 0
Latest GPCR
- SEC Form 10-Q filed by Structure Therapeutics Inc.
- Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.
- Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
- CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 10,626 units of Ordinary Shares, decreasing direct ownership by 8% to 258,228 units (SEC Form 4) (for tax liability)
- Structure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
- Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Latest LITS
- Lite Strategy Reports Fiscal 2027 First Quarter Financial Results
- SEC Form 10-Q filed by Lite Strategy Inc.
- Lite Strategy Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Director Glover Nicholas bought $12,550 worth of shares (2,000 units at $6.28) (SEC Form 4)
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
- SEC Form EFFECT filed by Lite Strategy Inc.